F-182112

N/A

Report date: 2026/05/13 20:02:10

Base Information

Drug NameF-182112
Drug Alias NameF-182112F182112
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD3Anti-BCMA
TargetsT cell surface glycoprotein CD3B-cell maturation protein
Therapy Area/IndicationsLupus Erythematosus, SystemicBone Marrow NeoplasmsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShandong New Time Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShandong New Time Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicBone Marrow NeoplasmsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A